Normal reference range of serum insulin-like growth factor (IGF)-I in healthy Thai adults
- PMID: 19127789
Normal reference range of serum insulin-like growth factor (IGF)-I in healthy Thai adults
Abstract
Background: Serum insulin-like growth factor (IGF)-I level is growth hormone (GH) dependent and reflects GH secretion. Analysis of IGF-I is a component in the diagnosis of GH-related disorders and is going to be of interest in determining the risk of many disorders such as cancer or atherosclerosis. The diagnosis value of IGF-I is dependent on the establishment of an accurate reference ranges, which can be affected by parameters such as age, gender, ethnicity, medications, chronic illness, or assay methodologies.
Objective: To determine reference ranges of IGF-I for healthy Thai adults.
Material and method: Eight hundred sixteen healthy Thai adults aged between 21-70 years were recruited in the present study. Serum IGF-I was measured by using immunochemiluminescent (ICMA; Roche, USA). Subjects were recorded by their age and gender groups. Data were presented in mean and +/- 2 standard deviation (SD). Correlation analysis between serum IGF-I and physical parameters including sex, age, weight, height, and body mass index (BMI) was also made.
Results: The present study demonstrated normal reference range of serum IGF-I by using mean +/- 2 SD value. The well-known age dependency of serum IGF-I levels was also revealed. Levels decreased with increasing age in both genders. The mean value of serum IGF-I was slightly higher in women at the age of 30-40 years compared with men in the same age group, but not statistically insignificant. In addition, serum IGF-I was found to correlate directly with the height and negatively with BMI. However, age-adjusted IGF-I level did not show correlation with these physical parameters.
Conclusion: This reference range will be beneficial for using IGF-I assay as a tool in the diagnosis of GH function abnormalities in Thai subjects.
Similar articles
-
Multidimensional reference regions for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum of healthy adults.Growth Horm IGF Res. 2008 Dec;18(6):506-16. doi: 10.1016/j.ghir.2008.04.005. Epub 2008 Jun 11. Growth Horm IGF Res. 2008. PMID: 18550406
-
Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).Growth Horm IGF Res. 2008 Aug;18(4):307-17. doi: 10.1016/j.ghir.2007.12.001. Epub 2008 Feb 20. Growth Horm IGF Res. 2008. PMID: 18282776 Clinical Trial.
-
Serum insulin-like growth factor-1 (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) in healthy Thai children and adolescents: relation to height, weight, and body mass index.J Med Assoc Thai. 1999 Oct;82(10):984-90. J Med Assoc Thai. 1999. PMID: 10561960
-
Does growth hormone prevent aging in the healthy elderly with low serum insulin-like growth factor-I ?Mech Ageing Dev. 2004 Apr;125(4):291-5. doi: 10.1016/j.mad.2004.01.005. Mech Ageing Dev. 2004. PMID: 15063105 Review.
-
Clinical laboratory indices in the treatment of acromegaly.Clin Chim Acta. 2011 Feb 20;412(5-6):403-9. doi: 10.1016/j.cca.2010.11.008. Epub 2010 Nov 12. Clin Chim Acta. 2011. PMID: 21075098 Review.
Cited by
-
Clinical characteristics and treatment outcomes in acromegaly, a retrospective single-center case series from Thailand.Pan Afr Med J. 2021 Sep 10;40:31. doi: 10.11604/pamj.2021.40.31.29920. eCollection 2021. Pan Afr Med J. 2021. PMID: 34795812 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical